TL1A as a therapeutic target in inflammatory bowel disease

被引：10
|
作者：
Kokkotis, Georgios [1 ]
Bamias, Giorgos [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sotiria Hosp, Dept Internal Med 3, GI Unit, Athens, Greece
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2022年 / 18卷 / 06期
关键词：
IBD; intervention; mucosal immunity; TL1A; TNFSF15; TNF-LIKE LIGAND; CYTOKINE; LYMPHOCYTES; EXPRESSION; CELL; 1A;
D O I：
10.1080/1744666X.2022.2074401
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：551 / 555
页数：5
相关论文
共 50 条
  • [21] An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease
    Clarke, Adam W.
    Poulton, Lynn
    Shim, Doris
    Mabon, David
    Butt, Danyal
    Pollard, Matthew
    Pande, Vanya
    Husten, Jean
    Lyons, Jacquelyn
    Tian, Chen
    Doyle, Anthony G.
    MABS, 2018, 10 (04) : 664 - 677
  • [22] Insights into TL1A and IBD Pathogenesis
    Shih, David Q.
    Michelsen, Kathrin S.
    Barrett, Robert J.
    Biener-Ramanujan, Eva
    Gonsky, Rivkah
    Zhang, Xiaolan
    Targan, Stephan R.
    ADVANCES IN TNF FAMILY RESEARCH, 2011, 691 : 279 - 288
  • [23] Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?
    Porter, Ross John
    Andrews, Caroline
    Brice, Daniel Paul
    Durum, Scott Kenneth
    McLean, Mairi Hall
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (10) : 2123 - 2134
  • [24] Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
    Verstockt, Sare
    Verstockt, Bram
    Vermeire, Severine
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (11) : 943 - 954
  • [25] The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease
    Wang, Lijian
    Trebicka, Estela
    Fu, Ying
    Ellenbogen, Shiri
    Hong, Charles C.
    Babitt, Jodie L.
    Lin, Herbert Y.
    Cherayil, Bobby J.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) : 112 - 119
  • [26] The role of NOD2 in intestinal immune response and microbiota modulation: A therapeutic target in inflammatory bowel disease
    Liu, Ziyue
    Zhang, Yaqin
    Jin, Tao
    Yi, Chengxue
    Ocansey, Dickson Kofi Wiredu
    Mao, Fei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [27] Regulatory T cells as a therapeutic approach for inflammatory bowel disease
    Laukova, Marcela
    Zaretsky, Arielle Glatman
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 (02)
  • [28] Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis
    Xu, Wangdong
    Su, Linchong
    Qing, Pingying
    Wang, Ying
    Liang, Yan
    Zhao, Yi
    Zhou, Qiongxiu
    Ma, Feng
    Liu, Yi
    CLINICAL RHEUMATOLOGY, 2017, 36 (06) : 1317 - 1324
  • [29] TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant
    Kayamuro, Hiroyuki
    Yoshioka, Yasuo
    Abe, Yasuhiro
    Katayama, Kazufumi
    Yoshida, Tokuyuki
    Yamashita, Kohei
    Yoshikawa, Tomoaki
    Hiroi, Takachika
    Itoh, Norio
    Kawai, Yuichi
    Mayumi, Tadanori
    Kamada, Haruhiko
    Tsunoda, Shin-ichi
    Tsutsumi, Yasuo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 384 (03) : 296 - 300
  • [30] TNF-like Ligand 1A (TL1A) Gene Knockout Leads to Ameliorated Collagen-Induced Arthritis in Mice: Implication of TL1A in Humoral Immune Responses
    Wang, Xuehai
    Hu, Yan
    Charpentier, Tania
    Lamarre, Alain
    Qi, Shijie
    Wu, Jiangping
    Luo, Hongyu
    JOURNAL OF IMMUNOLOGY, 2013, 191 (11) : 5420 - 5429
12345